Prophylaxis for Pneumocystis carinii has been standard care in HIV therapeutics for almost a decade. This year saw the results of clinical trials demonstrating effective prophylaxis for most of the main HIV-related opportunistic infections, systemic fungal, Mycobacterium avium complex and cytomegalovirus. However, in spite of effectiveness, it is unclear that survival is prolonged, and multiple prophylaxis is complicated by increased toxicity, drug-drug interactions, microbial resistance and cost.

Original languageEnglish
Pages (from-to)23-27
Number of pages5
JournalCurrent Opinion in Infectious Diseases
Issue number1
StatePublished - May 7 1996


Dive into the research topics of 'Opportunistic infections'. Together they form a unique fingerprint.

Cite this